Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.
The conversation is about a person experiencing hair loss, using topical minoxidil for 8 years, now at Norwood scale 3, and considering topical spironolactone and oral minoxidil after a tricho test recommendation. They are seeking others' experiences with topical spironolactone.
Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.
People on testosterone replacement therapy (TRT) with aggressive androgenetic alopecia (AGA) discuss using Dutasteride or Finasteride, sometimes combined with topical treatments like RU58841 or CB-03-01 (Breezula), to prevent hair loss. Concerns about side effects and costs of certain treatments are mentioned, with one individual sharing their experience of slowed hair loss using Finasteride alone.
Finasteride is key for hair regrowth, supported by oral/topical minoxidil, Folexin, Nizoral/Head & Shoulders, and vitamin D. No side effects experienced; early intervention and patience are crucial.
Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.
Dutasteride users report mixed experiences, with some experiencing significant hair shedding and others seeing improvement after initial shedding. Many users switch from finasteride to dutasteride, hoping for better results, but reactions vary widely, with some facing allergies or worsening hair loss.
Hair regrowth from treatments like minoxidil, RU58841, and finasteride is not permanent; stopping these treatments typically results in hair loss resuming. Beard hair can become permanent with minoxidil use, unlike scalp hair, which requires ongoing treatment to maintain gains.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
A 27-year-old woman with androgenic alopecia is losing hair despite using oral minoxidil and spironolactone, and is considering dutasteride. She is exploring causes like stress and medication side effects, planning tests, and considering treatment changes.
Dutasteride has effectively stopped hair loss for some users, while others continue to experience shedding despite using dutasteride, finasteride, and minoxidil. Some users report side effects like erectile dysfunction when switching from finasteride to dutasteride.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.
Finasteride effectively treated hormonal acne for multiple users, including the original poster. Topical treatments like Winlevi are effective but expensive and not always covered by insurance.
The user applied Kindor's KU, followed by a solution of Finasteride, Minoxidil, and Tretinoin for alopecia. They experienced no side effects from Kindor's KU.
The user experienced erectile dysfunction from 1mg finasteride and sought advice on whether to continue, reduce dosage, or switch treatments. Suggestions included switching to topical finasteride, adding minoxidil, or trying dutasteride.
A 20-year-old lost significant hair after one year of treatment, using minoxidil, finasteride, and later dutasteride. They are considering adding RU58841 but are advised to return to finasteride and minoxidil for a year before deciding.
The user is using finasteride, dutasteride, Nizoral, biotin, RU58841, minoxidil, Pantostin/Alfatradiol, Stemoxydine, and micro needling for hair loss. They are considering adding oral minoxidil.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.
Switching from finasteride to dutasteride involves gradually increasing dutasteride while decreasing finasteride. Studies show dutasteride 0.5 mg daily can improve hair density in men unresponsive to finasteride.
A 31-year-old who experienced severe hair loss during medical school tried various treatments, including topical and oral finasteride and minoxidil, but stopped due to side effects. They restarted treatment 10 months ago with a regimen including topical finasteride, minoxidil, retinoic acid, hydrocortisone, oral minoxidil, and light therapy, emphasizing the importance of consistency and skincare.
The conversation suggests that a 22-year-old male may regrow his hair using dutasteride and minoxidil without needing a hair transplant, advising to continue treatment and assess progress after 1-2 years.
Finasteride, a hair loss treatment, was observed to reduce scalp oiliness in users. Anti-androgens like Finasteride are known to decrease the activity of oil-producing glands.